Detalhe da pesquisa
1.
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
Hepatology
; 78(6): 1843-1857, 2023 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37222264
2.
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
Liver Int
; 44(4): 966-978, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38293761
3.
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
J Hepatol
; 73(1): 94-101, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32165251
4.
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet
; 394(10215): 2184-2196, 2019 12 14.
Artigo
Inglês
| MEDLINE | ID: mdl-31813633
5.
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.
Clin Gastroenterol Hepatol
; 18(5): 1170-1178.e6, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31606455
6.
Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis.
Liver Int
; 40(5): 1121-1129, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32145129
7.
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
N Engl J Med
; 375(7): 631-43, 2016 Aug 18.
Artigo
Inglês
| MEDLINE | ID: mdl-27532829
8.
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Liver Int
; 39(11): 2082-2093, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31402538
9.
Clinical endpoints are necessary in the interim analysis of REGENERATE - Authors' reply.
Lancet
; 396(10252): 663-664, 2020 09 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32891200
10.
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
Cardiovasc Diabetol
; 14: 12, 2015 Feb 03.
Artigo
Inglês
| MEDLINE | ID: mdl-25645567
11.
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Br J Clin Pharmacol
; 75(4): 979-89, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-22882281
12.
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Lancet
; 376(9739): 431-9, 2010 Aug 07.
Artigo
Inglês
| MEDLINE | ID: mdl-20580422
13.
Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis.
JHEP Rep
; 3(1): 100191, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-33319187
14.
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.
Cardiovasc Diabetol
; 9: 6, 2010 Jan 28.
Artigo
Inglês
| MEDLINE | ID: mdl-20109208
15.
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
Lancet Gastroenterol Hepatol
; 4(6): 445-453, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30922873
16.
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Contemp Clin Trials
; 84: 105803, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31260793
17.
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Clin Ther
; 30(8): 1448-60, 2008 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-18803987
18.
Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis.
Hepatol Commun
; 2(6): 683-692, 2018 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-29881820
19.
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Adv Ther
; 34(9): 2120-2138, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28808886
20.
Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.
Diabetes Care
; 39(10): 1768-76, 2016 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-27436275